We are live on !
Find out more
Affinity Asset Advisors Portfolio holdings
AUM
$2.21B
Turnover
29.69%
1-Year Est. Return
431.26%
This Fund
S&P 500
This Quarter Est. Return
+29.83%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$2.21B
AUM Growth
+$276M
(+14%)
Cap. Flow
-$34.2M
Cap. Flow % of AUM
Cap. Flow %
-1.55%
Top 10 Holdings %
Top 10 Hldgs %
39.41%
Holding
128
New
23
Increased
32
Reduced
32
Closed
15
Avg Time Held
Equity + Options
1
year
Top 10 Avg Time Held
Equity + Options
0.8
years
Top 20 Avg Time Held
Equity + Options
0.7
years
Avg Time Held Equity only
1.1
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
First Tracks Biotherapeutics
TRAX
|
+$38M |
| 2 |
Roivant Sciences
ROIV
|
+$28.1M |
| 3 |
Avalo Therapeutics
AVTX
|
+$24.6M |
| 4 |
Revolution Medicines
RVMD
|
+$21.9M |
| 5 |
Insmed
INSM
|
+$20.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$55.6M |
| 2 |
Arcellx
ACLX
|
+$41.7M |
| 3 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$34.2M |
| 4 |
Terns Pharmaceuticals
TERN
|
+$29.7M |
| 5 |
Apogee Therapeutics
APGE
|
+$26.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.73% |
| 2 | Miscellaneous | 9.21% |
| 3 | Financials | 1.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
51
Teva Pharmaceutical Industries Limited
TEVA
$46.9B
| $12.7M | 0.57% |
374,000
-1,026,000
| -73% | -$34.2M |
2023 Q2
12 quarters
|
|
52
Veradermics Inc
MANE
$5.79B
| $12.3M | 0.56% |
100,000
+30,000
| +43% | +$2.81M |
2026 Q1
1 quarter
|
|
53
Arrowhead Research
ARWR
$8.24B
| $12.2M | 0.55% |
150,000
-50,000
| -25% | -$3.69M |
2025 Q4
2 quarters
|
|
54
Taysha Gene Therapies
TSHA
$1.3B
| $11.9M | 0.54% |
1,750,000
+750,000
| +75% | +$4.44M |
2025 Q2
4 quarters
|
|
|
DMRA
55
Damora Therapeutics
DMRA
$1.34B
| $11.1M | 0.5% |
425,000
-25,000
| -6% | -$605K |
2026 Q1
1 quarter
|
|
56
Eupraxia Pharmaceuticals
EPRX
$501M
| $10.9M | 0.49% |
1,650,000
+60,995
| +4% | +$421K |
2025 Q3
3 quarters
|
|
57
Vera Therapeutics
VERA
$2.09B
| $10.7M | 0.48% |
250,000
| – | – |
2024 Q1
9 quarters
|
|
58
ProQR Therapeutics
PRQR
$188M
| $10.3M | 0.47% |
5,543,936
+3,089,658
| +126% | +$5.09M |
2024 Q4
6 quarters
|
|
59
NewAmsterdam Pharma
NAMS
$2.58B
| $9.32M | 0.42% |
275,000
| – | – |
2023 Q2
12 quarters
|
|
60
Korro Bio
KRRO
$177M
| $9.32M | 0.42% |
706,904
| – | – |
2026 Q1
1 quarter
|
|
61
CALL
uniQure
QURE
$1.6B
| $9.21M | 0.42% |
200,000
-100,000
| -33% | -$2.62M |
2025 Q4
2 quarters
|
|
62
Anteris Technologies
AVR
$585M
| $8.99M | 0.41% |
912,397
| – | – |
2024 Q4
6 quarters
|
|
63
Zura Bio
ZURA
$338M
| $8.64M | 0.39% |
1,464,303
-1,100,000
| -43% | -$5.24M |
2024 Q1
9 quarters
|
|
|
64
uniQure
QURE
$1.6B
| $8.06M | 0.36% |
+175,000
| New | +$4.58M |
2026 Q2
0 quarters
|
|
65
Ascendis Pharma A/S
ASND
$16B
| $8M | 0.36% |
30,000
-65,000
| -68% | -$15.2M |
2025 Q4
2 quarters
|
|
66
iBio
IBIO
$50.4M
| $7.01M | 0.32% |
4,007,881
+900,681
| +29% | +$1.61M |
2025 Q4
2 quarters
|
|
67
Generate Biomedicines
GENB
$1.64B
| $6.75M | 0.31% |
400,000
+50,000
| +14% | +$681K |
2026 Q1
1 quarter
|
|
68
PUT
Evommune Inc
EVMN
$189M
| $6.65M | 0.3% |
+500,100
| New | +$11.6M |
2026 Q2
0 quarters
|
|
69
Tyra Biosciences
TYRA
$1.43B
| $6.39M | 0.29% |
200,012
-57,500
| -22% | -$1.9M |
2026 Q1
1 quarter
|
|
70
Sol-Gel Technologies
SLGL
$221M
| $6.29M | 0.28% |
84,900
+49,900
| +143% | +$3.66M |
2026 Q1
1 quarter
|
|
71
SAB Biotherapeutics
SABS
$277M
| $5.95M | 0.27% |
1,525,000
+950,000
| +165% | +$3.53M |
2026 Q1
1 quarter
|
|
72
MacroGenics
MGNX
$231M
| $5.62M | 0.25% |
1,216,606
+716,606
| +143% | +$2.71M |
2025 Q4
2 quarters
|
|
73
CRISPR Therapeutics
CRSP
$4.83B
| $5.45M | 0.25% |
100,000
-50,000
| -33% | -$2.64M |
2026 Q1
1 quarter
|
|
|
74
NewAmsterdam Pharma Warrant
NAMSW
$42.6M
| $5.34M | 0.24% |
245,000
| – | – |
2023 Q1
13 quarters
|
|
75
Assembly Biosciences
ASMB
$413M
| $5.22M | 0.24% |
+190,000
| New | +$5.17M |
2026 Q2
0 quarters
|
|
Similar funds
Affinity Asset Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Affinity Asset Advisors held 128 positions worth $2.21B, up 14% from $1.94B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Affinity Asset Advisors's Q2 2026 filing shows 23 new, 32 increased, 32 reduced and 15 closed positions. Its largest new stake was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M. The largest sale was Centessa Pharmaceuticals, an estimated $55.6M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Financials.
- Affinity Asset Advisors's largest Q2 2026 buy was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M.
- Affinity Asset Advisors added most to Roivant Sciences in Q2 2026, an estimated $28.1M increase.
- Affinity Asset Advisors's biggest Q2 2026 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $34.2M.
- Affinity Asset Advisors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $55.6M.
- Affinity Asset Advisors's ten largest holdings make up 39% of its $2.21B portfolio in Q2 2026.
- Affinity Asset Advisors opened 23 new positions and closed 15 in Q2 2026.
- Affinity Asset Advisors's portfolio value rose 14% quarter-over-quarter to $2.21B.
Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.